quickli thing chang
earn preview outlookbiotech
find offens within defens sector pandem larg cap biotech
held well sector substanti outperform broader marketsinc jan
largest name averag vs view
multipl factor driven perform includ relat headlin gilead
regeneron un-rel competit updat regeneron believ
renew interest generalist prior overhang drug price vanish
least temporarili despit posit bia toward sector believ certain name
set best weather headwind also perform well
long-term head earn vertex prefer name given extrem limit
exposur pandem also long-term growth driven strong cf franchis
believ vertex like name like beat rais quarter
opposit end spectrum concern neurocrin vs name
coverag think season ingrezza like impact result coupl
could potenti poorer outlook beyond due pandem overal
expect quantit assess busi impact similar
frame guidanc expect coverag outright pull guidanc
gener expect biotech pharma hold rel well vs sector within
outsid healthcar stock specif view throughout report
op tp guidanc like longer conserv weve brought
number within rang expect otezla soft year think biosimilar
might stronger expect question oncolog clinic catalyst
vertex- op new tp insul name like set beat-
and-rais quarter strong trikafta launch delay clinic trial unlik impact
sentiment given continu growth stori beyond top pick
gilead- new tp high-level investor interest potenti remdesivir
treatment still concern busi issu relat pandem
prep yescarta like impact upcom launch filgotinib
 new tp question aducanumab file
sentiment echo investor given dearth substant updat sinc earli march less
concern ms franchis potenti spinraza pandem
regeneron- op new tp high-level interest potenti treatment covid-
despit concern eylea dupix near-term think long-term
fundament remain strong detail new account expens guidanc like
 new tp jakafi busi remain insul weve
maintain within guidanc estim concern remain launch tafasitamab
pemigatinib pandem
neurocrine- new tp ingrezza soft expect neg trend could
continu beyond opicapon launch also delay due suppli issu covid-
relat concern clinic catalyst/ trial delay well
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
tabl content
select trx y/i growth amgen product
iqvia script trend earn hiv
layer magrolimab md dlbcl fortyseven acquisit
companydatetimedial-inbiogenapril etu confer id etn/alillyapril etn/asanofiapril etn/abayerapril etn/anovartisapril etn/apfizerapril etu confer id first quarter earningsmerckapril etu confer id etn/aglaxosmithklineapril etn/avertexapril pm etu gileadapril pm etu confer id amgenapril pm etu confer id etu confer id abbvieincytemay etu confer id regeneronmay etu confer id n/aneurocrinemay pm etu confer id nbixbristol-my squibbmay etn/agalapago may etn/a galapago pr releas may charl martineau pm univers toronto april
name held well sinc begin year return past week
also gener strong see figur
figur biotech perform past week ytd
perform gilead like driven remdesivir updat includ recent
anecdot compani sponsor trial see ye initi remdesivir data hint
encourag think recent perform fulli factor impact less
prep use less truvada descovi switch potenti cell-therapi weak
concern pandem make compani goal convert current truvada prep
patient descovi ahead late septemb launch gener much difficult
see examin emerg trend potenti impact hiv landscap
physician also unlik start new cell therapi treatment current environ
especi costal oncolog center
regeneron perform like tie februari competit updat american
societi retin specialist warn potenti seriou side-effect novarti recent
launch beovu see competitor stumbl ophthalmolog recent perform
tie relat work long-term visibl partnership account
like help investor feel comfort model regeneron
think becom sourc fund given strong perform
question compani commerci perform pandem think
fine vertex hand perform nearli well gilead without covid-
treatment headlin benefit think share becom safer avenu revenu
earn growth independ rel perform like
due increas question aducanumab filingwith thing hear
investor file agre earli target pass
wonder reason perceiv delay
modestli ytd less headlin although compani studi
jakafi potenti treatment cytokin storm associ sever patient
recent approv pemigatinib also minim impact namegiven small
indic concern launch drug pandem
note neurocrin under-perform think investor grow concern
long-term potenti ingrezza soft expect trend could
continu beyond absent clinic catalyst near-term find difficult see
upsid share next year
preview believ
conserv guid becom
potenti impact cut revenu ep forecast
amgennot bring estim within guidanc previous
frame guidanc revenu non-gaap ep
conserv allow new cfo set beat-and-rais year given
potenti impact cut revenu estim
non-gaap esp estim think
much busi rel defens somewhat concern
potenti soft come notabl cut estim prolia iqvia
script suggest y/i declin late march indic fewer inject like
continu long wide-spread lock down action aimovig trx trend show
y/i declin suggest near zero growth also cut otezla number
year essenti forecast flat ww sale given growth like driven
sale rep interact virtual posit note expect continu
adopt biosimilar continu momentum begin year
heard anecdot institut delay switch biosimilar due suppli
concern note reliabl suppli also believ increas
financi pressur institut due drive cost save measur
also align commentari roch biosimilar exposur
despit increas headwind think remain stalwart among
larg cap biotech pharma namessupport outperform rate
focu point call follow recent discuss manag expect
granular potenti impact busi could get
revis guidanc compani enough insight perform
altern compani could rescind current guidanc see unlik along
line expect continu discuss launch biosimilar us
project biosimilar sale per call could also get detail
impact clinic trial due coronavirusnot impact/ updat
still color potenti data virtual meet
unlik get addit color recent enbrel ip appeal
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biotechnolog compani engag discoveri
develop manufactur market human therapeut
blue sky scenario assum tvgr better current
assumpt base-busi greater current
forecast assum greater expect growth biosimilar
franchis slower expect declin base busi
also assum posit data readout pipelin asset
base busi sale poorer growth profil biosimilar
busi key pipelin asset assum slower expect
growth biosimilar franchis also assum neg data
readout pipelin asset
 close
select trx y/i growth amgen product
model chang updat model reflect view on-going trend
notabl cut total revenu estim concern relat
within guidanc vs ahead previous forecast non-
gaap ep estim within guidanc slightli consensu
estim figur detail
valuat price target deriv dcf analysi use wacc
previous termin growth previous adjust wacc given recent
chang bloomberg wacc calcul forecast cash flow account
known expect product launch patent expir competit threat
current commerci portfolio pipelin tp remain figur
amgen inc revenu incom dilut charl martineau pm univers toronto april
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv investig product
commerci sale
preview like insul
delay trial
vertex core cf busi like insul alreadi
strong forecast trikafta maintain number continu
forecast ww cf revenu vs consensu bottom-lin
maintain non-gaap ep estim vs consensu
bullish view commerci busi base fact vertex medicin
life-threaten rare diseas administ home requir frequent
physician visit therapeut altern essenti patient
also note vertex maintain small commerci forc drive revenu
via tradit sale rep engag modelthu work home mandat
unlik impact commerci progress european outlook less certain
think patient still get medicin anyth on-going access negoti may
delay symkevi franc weve maintain sg number
although trial paus could see less spend year alreadi
consensu expect vs consensu given
insul top pick among larg cap name
expect non-gaap product revenu guidanc maintain
unlik increas non-gaap sg guidanc also
like reiter
given vertex rel strength weve increas tp updat
valuat methodolog weve cut wacc lower rel risk
broader market line recent declin bloomberg wacc weve also cut
termin valu growth rate tp base sum
part dcf analysi ep chang valuat
risk commerci market price regulatori
focu point call expect discuss on-going launch trikafta
includ trend seen begin late march interest level
penetr het-min popul us patient activ switch
symdeko orkambi trikafta
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset
gene-edit system
grey sky scenario model less credit trikafta due lower
expect commerci perform regulatori delay
 close
addit like focu point call vertex also like discuss state
european market follow ema applic valid back octob
call januari compani expect approv patient year cours
vertex transpar potenti impact expect
color state variou clinic trial paus last month
vertex mileston call await see ultim impact
compani score card expect delay trial includ
close watch phase trial start januari proof-of-concept data
plan figur vertex goal mileston provid prior
figur vertex goal milestones- prior
model chang weve made essenti substanti chang vertex model
remain slight ahead non-gaap revenu guidanc guidanc
consensu note project non-gaap tax rate line
guidanc higher consensu forecast risk adjust
revenu non-cf product includ beta-th sickl cell program
fsg diabetesw substant chang make even program delay
figur detail
valuat weve increas target price given chang valuat
metric assumpt across coverag seen decreas bloomberg wacc
sinc thu cut wacc assumpt share
basi dcf analysi also cut termin valu growth rate tvgr
given potenti delay product due forecast cash
flow account known expect product launch patent expir
competit threat current commerci portfolio pipelin figur
vertex residu cf opportun ex cf opportun ex revenu loss incom cs dilut cs cfopportunityfrench cfopportunityother/unallocated/corporatenet charl martineau pm univers toronto
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
revis grey scenario
revis scenario assum dcf valu
share cut sg respect assum posit proof-of-
concept data next gener cf asset also assum posit
data updat pipelin asset gene-edit system
grey sky scenario model less credit trikafta due lower
expect commerci perform regulatori delay unfavor reimburs
preview dont miss forest
tree remdesivir unlik address
head result much narr gilead remain
develop remdesivir treatment myopic view fail
consid long-term issu compani simpli put despit near-term
benefit remdesivir littl resolv fundament concern share
result convers prep patient truvada descovi like
significantli impact yescarta sale could also declin even concern
potenti launch filgotinib alreadi bearish pandem
notwithstand given dynam think product sale earn
guidanc non-gaap respect could risk
forecast product sale non-gaap ep
notabl sale guidanc includ benefit driven us hiv
treatment prevent prep us/china vemlidi hbv growth cell therapi
ramp/expans us europ could see hiv treatment growth
switch unlik pandem addit believ prep use like
declin pandem window switch patient truvada descovi
quickli close check suggest gilead rep activ push prep switch
gener avail believ switch difficult still
comfort long-term set think remdesivir bump like
temporari support under-perform rate wacc adjust
layer ftsv model revis tp
number like fine hiv patient treatment prevent
get day rxsimpact like magnifi come iqvia trend suggest
number fine still typic season biktarvi
entir hiv biz weve also cut yescarta number bring
con total revenu slightli behind consensu
vs bottom line non-gaap ep estim vs
consensu
valuat tp base sum part dcf analysi risk commerci
market price regulatori
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc biopharmaceut compani engag
research develop commerci medicin
area infecti diseas oncolog immunolog area
sky scenario model probabl success
yescarta expans well filgotinib also assum higher po
magrolimab maintain base case third line yescarta hiv hcv
grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay fail
meet base-cas expect nash program fail
maintain base case third line yescarta hiv hcv sale
 close
focu point call mani question may focu remdesivir develop
interest potenti guidanc revis impact prep yescarta
upcom launch filgotinib could get color ftsv acquisit
thought busi develop
iqvia script trend earn hiv
nbrx vs trend suggest earli sign impact though biktarvi remain
highlight nbrx vs recent trend key hiv drug gilead biktarvi vs viiv
dovato juluca triumeq see biktarvi overshadow brand
nbrx note whilst biktarvi fluctuat nbrx per week throughout
date exclud usual dip around holiday trend sky
rocket increas absolut weekli last month clear
trend somewhat inflat wholesal stock effect given recent
trend biktarvi could see sale resili despit environ
given higher need hiv patient continu medic would expect
prescrib maintain continu care popul like virtual script refil
figur weekli nbrx
figur weekli nbrx biktarvi dovato juluca triumeq
figur weekli trx biktarvi dovato juluca triumeq
weaker trend dovato note weaker expect prescript trend dovato
far year averag week week growth expect
greater growth follow addit dovato dhh guidelin link initi
regimen treatment hiv back decemb howev given first time
complet recommend set dhh physician familiar may
lower like engrain clinic practic convers
physician regimen prefer gilead biktarvi
highlight similar weak juluca trend although reflect real world usag
due report restrict collect trend like enough make
declin seen viiv triumeq tivicay overal gsk guid hiv portfolio
broadli flat
nbrx impact due switch increas telemedicin
given current disrupt anticip less patient switch
new medicin fewer clinic visit telemedicin base appoint
also view newer drug market year promot sensit
expect may suffer heavili time social distanc mandat forc
rep shift digit base market believ start reflect nbrx trend
drug data show biktarvi dovato juluca last
consecut week data look monitor data come week
disrupt healthcar system us intensifi
layer magrolimab md dlbcl
follow earli march acquisit fortyseven gilead recent close
transact ad magrolimab model md myelodysplast
syndrom later-lin dlbcl assum po unadjust peak sale
magrolimab contribut addit dcf also adjust
cash balanc reflect purchas price previous indic
like deal think enough move needl near-term earn
revenu assum sale least resolv larger concern
name figur figur detail magrolimab market model
figur magrolimab md us sale unadjust
high risk market modelannu incid high int high elig treat market treat growth price per us magrolimab sale charl martineau pm univers toronto april
figur magrolimab dlbcl us sale unadjust
diffus larg b-cell lymphoma dlbcl market modelpopul incid receiv treat relapsing/inelig relapsed/refractori relapsing/inelig relapsed/refractori elig treat market patient growth price per us magrolimab sale charl martineau pm univers toronto april
model chang weve updat model reflect concern surround impact
gilead busi biktarvi number slightli ahead consensu
think patient may get day refil pandem mani insur compani
allow fill still given concern around prep cut number
fy addit yescarta consensu non-gaap ep
revenu fy non-gaap ep guidanc consensu
product sale estim lower end guidanc
consensu figur detail
figur estim cs vs consensu
valuat target price deriv dcf analysi use wacc
previous given observ reduct bloomberg wacc
cover compani weve also decreas termin valu growth rate
previous forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin analysi result tp figur
gilead axicabtagen franchis ex product revenu includ glpg incom cs loss incom cs dilut cs million consconsguidanceconsc vs charl martineau pm univers toronto april
grey scenario remain unchang
scenario- sky scenario model probabl success
yescarta expans well filgotinib also assum higher po magrolimab
maintain base case third line yescarta hiv hcv sale
grey scenario- grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay fail meet base-cas
expect nash program fail maintain base case third line yescarta hiv
hcv sale
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv gilead investig product
commerci sale
preview still wait updat
head earn key question investor mind
aducanumab file view financi result long number
fall cliff matter much less updat file still look quarter
think tecfidera fine cs essenti in-lin consensu ww
sale use iqvia data estim us sale around detail analysi
later section wholesal built extra inventori toward end quarter
due concern could see revenu bump total ms product
in-line believ asid typic season
minim impact due coronaviru anyth could see soft
tysabri sale believ patient may delay infus product tecfidera
interferon impact slightli spinraza
vs possibl patient unabl get therapi due covid
especi end quarter pandem hit us europ end
slightli cut spinraza number note pdufa delay
risdiplam could help off-set commerci headwind due pandem biogen
typic updat guidanc call unsur compani deviat
updat number due pandem overal remain sidelin
await progress updat aducanumab file regulatori progress
consist across coverag bloomberg wacc come sinc
across name given cut wacc
think remain risk aducanumab tecfidera given district court case
weve also cut tvgr result revis tp
tp base sum part dcf analysi risk commerci market
price regulatori
focu point call expect question focu aducanumab file
weve yet get clariti beyond make good progress file
soon possibl beyond aducanumab expect commentari impact lack
thereof includ commerci busi clinic trial across
franchis expect substant discuss us district court case
challeng tecfiderawith decis potenti around mid-year could delay
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma risdiplam
zolgensma either fail clinic take meaning share
aducanumab approv use major address
grey scenario assum ms franchis declin greater
expect rate new therapi take greater expect share
near-term zolgensma captur major new incid
sma market long-term spinraza lose share risdiplam
preval sma market aducanumab approv
 close
tecfidera model report actual us tecfidera sale
inventori build off-set inventori drawdown
assum inventori build drawn could posit impact
wholesal add inventori usual given off-set modest
increas demand iqvia number slight price increas assum
price increas flows-through given like higher gross-to-net analyz
lever get us approxim us tecfidera revenu see figur
figur analysi tecfidera lever vs
model chang given on-going dynam mainli relat updat
model slightli posit tecfidera think fewer patient
switch product expect bia toward oral ms therapi vs infus due
expens side expect impact
paid sangamo part global collabor announc late februari
assum up-front paid expens equiti invest like record
balanc sheet slightli ahead consensu revenu non-
gaap ep vs vs fy in-lin revenu
slightli non-gaap ep vs expens
sangamo collabor figur detail
figur estim cs vs consensu
valuat one -year price target deriv base -case dcf
analysi assum wacc wacc weight averag cost capit
termin growth rate project cash flow year
account known expect competitor launch patent expir beyond
forecast period believ replac revenu lost eros challeng given biogen
earlier stage pipelin priorit share repurchas bd figur detail
inc ms product biosimilar revenu incom dilut charl martineau pm univers toronto april
scenario share assum current market ms franchis
experi greater expect degre eros competit eros
occur partial off-set sale vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take meaning share
aducanumab approv use major address patient
grey scenario share assum ms franchis declin greater
expect rate new therapi take greater expect share near-term
zolgensma captur major new incid sma market long-term spinraza lose
share risdiplam preval sma market aducanumab approv
clinic development valuat share upsid potenti base
outcom clinic trial late -stage asset shown clinic
ineffect unsaf would expect neg pressur share
regulatori risk drug fda approv note extraordinari case fda
interven post -approv retroact remov approv statu
commerci risk new entrant marketplac could add competit pressur
marketplac exist competitor may produc drug prove efficaci and/or
safer factor lead lower adopt rate market drug could
price risk signific chang price could consider impact revenu forecast
valu share drug price current key topic polit debat
price could affect polici chang
market risk histor volatil sector unpredict market forc
exist could disrupt equilibrium investor may bearish biotechnolog
potenti drug price legisl may choos put capit use elsewher
consensu number question remain near-
ahead earn updat regeneron model reflect
praluent restructur new account present regeneron model
current transit await close kevzara restructur notabl
jan expens reimburs collabor longer book
collabor revenu expens book regeneron incur
expens adjust result revenu declin impact
net incom ep tax us praluent sale book
regeneron ou book sanofi parti pay mid-singl digit royalti
assum given potenti impact especi eylea dupix
also cut number temporarili year us eylea number
fy bayer collabor revenu ou eylea profit split
fy sanofi collabor number
fymainli driven account chang also less dupix
growth consensu number collabor revenu like inaccur model
updat despit potenti near-term weak remain posit
share long-term howev remov top pick
consist analysi recent bloomberg wacc chang cut
regeneron wacc bloomberg wacc regeneron
given near-term risk cut
wacc weve also cut tvgr tp increas
use dcf analysi risk commerci market price regulatori
focu point call expect continu discuss new account
present granular model subsequ quarter also expect
regeneron provid guidanc includ expens guidanc aim provid
granular past consist prior preced expect revenu us
eylea ep guidanc still expect commentari perform eylea
dupix includ potenti impact due beyond commerci
busi expect manag review progress kevzara anti-bodi
cocktail treatments/ prophylaxi coronaviru could also get updat
novel oncolog pipelin includ data expect data
interim look libtayo nsclc
valuat metric
number share
 close
price
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc engag discoveri invent
develop manufactur commerci medicin
treatment seriou diseas
scenario assum less impact biosimilar eylea
us ou via bayer collabor end-us
dupix sale peak estim addit success
novel oncolog platform libtayo lung among
asset assum scenario
grey scenario assum greater impact biosimilar eylea
competit share loss beovu also assum greater
competit ad asthma space impact peak dupix
forecast final grey scenario assum work
novel oncolog platform unabl expand pi libtayo
unsuccess develop clinical-stag asset
 close
dupix growth appear healthi late march/ earli april remain
encourag growth trend dupix note y/i growth continu
april data exclud ou sale may paint entir pictur us sales/
demand trend slow would expect see growth declin amgen
model updat regeneron model updat extens given chang
account praluent restructur updat thought commerci busi
note regeneron yet provid guidanc metric overal reduc margin
name due account chang gener expect sg spend
exclud relat trial unlik grow significantli forecast
lower sg spend mostli due account chang pleas ask
updat model includ recent announc updat
sanofi collabor jan updat account present reflect
updat praluent still includ sanofi collabor profit share kevzara
remain well restructur close deal-term announc
sanofi collabor revenu mostli shift expens reimburs
approxim fy cut sanofi collabor revenu
expens reimburs given potenti impact
model ww dupix end-us sale prior recal still includ
collabor essenti profit-shar regeneron sanofi sanofi
continu book ww revenu product libtayo number us remain
adjust expens ou profit splithowev neglig
impact broader
eylea remain concern eylea salesassum lock
associ pandem remain regard throughout summer
like suggest elderli diabet remain isol fy cut eylea
number major impact seen
number return normal assum pandem control even
absent broadli avail vaccin see similar issu ou cut bayer collabor
revenu fy forecast bayer collabor profit
prior vs consensu impact account chang collabor
minim littl expens reimburs develop
pdgfr-beta antibodi previous discontinu still reimburs
eylea develop expens prior period current
regardless amount nomin minim impact collabor revenu
still remain posit eylea beyond given recent asr recommendation/
concern novarti beovu see competitor stumbl ophthalmolog
figur chang detail view vs consensu across metric note
consensu mani reflect new account present name sanofi collabor
figur regn- estim cs vs consensu
valuat consist across coverag adjust wacc assumpt
regeneron use wacc still current bloomberg wacc
approxim also cut tvgr continu cash
flow account known expect product launch patent expir
competit threat current commerci portfolio pipelin given chang
increas tp figur detail
million priorcurrentchangepriorcurrentchangepriorcurrentchangeeylea collabor mab i/o updat revenu loss incom dilut charl martineau pm univers toronto april
scenario scenario assum less impact
biosimilar eylea us ou via bayer collabor end-us
dupix sale peak estim addit success novel oncolog
platform libtayo lung among asset assum
grey scenario grey scenario assum greater impact
biosimilar eylea competit share loss beovu scenario
current safeti concern impact long-term sale also assum greater competit
ad asthma space impact peak dupix forecast final grey
scenario assum work novel oncolog platform unabl expand pi
libtayo unsuccess develop clinical-stag asset
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv regeneron investig
product commerci sale
preview rel insul
discuss like center
tafasitamab pemazyr launch
head earn expect surpris given in-lin
view us sale still note consensu expens yet updat
reflect morphosi deal us jakafi sale vs
consensu essenti in-lin given believ rel stabl consist
busi highlight consensu appear reflect expens up-front
cost morphosi deal specif non-
includ addit impli premium invest
chang result signific net-loss non-gaap ep
vs consensu prior ep estim given also
expect updat expens guidanc conjunct earn call
pemigatinib approv cholangiocarcinoma fda approv nda pemigatinib
pemazyr cholangiocarcinoma ahead may pdufa given
posit data alreadi assum po thu approv substanti chang
model cholangiocarcinoma rare cancer less peak sale
prior discuss readi launch asset even despit pandem
unlik impact commerci busi near-term clinic trial
read-out still expect discuss call trial risk delay
could also get detail use jakafi potenti treatment
revis wacc tvgr assumpt addit revis expens
assumpt increas tp use wacc
tvgr weve also moder long-term
expens fulli valu pemigatinib opportun cholangiocarcinoma tp
base sum part dcf analysi risk commerci market price
regulatori reiter neutral rate share
focu point call asid discuss expect
addit color regulatori progress/ plan ruxolitinib cream ad progress
limber initi could get commentari potenti launch tafasitamab
given pdufa
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari therapeut
oncolog hematolog dermatolog
blue sky base fda approv pemigatinib ruxolitinib cream
within next month success commerci
pemigatinib cholangiocarcinoma tafasitamab also assum
better expect jakafi revenu
grey sky downsid assum fda approv ruxolitinib
cream commerci pemigatinib cholangiocarcinoma
tafasitamab wors expect grey sky also assum neg
data readout pemigatinib urotheli cancer also assum
jakafi revenu lower expect
 close
figur incyt expect news provid prior
model chang weve mainli updat expens assumpt reflect close
morphosi deal weve maintain revenu assumpt
given chang forecast ep loss modest
ep consensu expect yet updat reflect close
morphosi deal weve also moder expens detail see figur
figur incy- estim cs vs consensu
incyt corpor million priorcurrentchangepriorcurrentchangepriorcurrentchangejakafi ruxolitinib sale ruxolitinib ad ruxolitinib royalti revenu loss incom cs dilut cs charl martineau pm univers toronto april
valuat one-year price target deriv base-cas dcf analysi
use discount rate lower bloomberg wacc believ
discount rate reflect risk futur cash flow weve also adjust tvgr
given loe risk jakafi neg view pipelin prospect
note year experi commerci jakafi view
best-in-class product current minim near-term competit threat figur
blue sky upsid case valuat base fda approv pemigatinib
ruxolitinib cream within next month success commerci
pemigatinib cholangiocarcinoma tafasitamab also assum better expect jakafi
grey sky downsid valuat assum fda approv ruxolitinib
cream commerci pemigatinib cholangiocarcinoma tafasitamab
wors expect grey sky also assum neg data readout pemigatinib
urotheli cancer also assum jakafi revenu lower expect
clinic development valuat share upsid potenti base
outcom clinic trial late-stag asset shown
clinic ineffect unsaf would expect neg pressur share
regulatori food drug administr fda european medicin agenc ema
regulatori bodi approv requir market sell
therapeut delay outright reject approv investig asset could
neg impact futur cash flow valu share furthermor
fda ema could revok market author market product due
safeti efficaci concern
commerci eu sale us sale royalti drive major cash flow
earn estim sale wors consensu expect could see
neg impact share
external/market risk biotechnolog remain volatil sector affect
overal economi neg polici develop and/or weaken
could headwind continu
focu remain ingrezza season could impact
inventori current forecast ingrezza sale vs
consensu continu expect new
patient add headwind expect multipl angl also note
benefit inventori could increas q/q declin sale
key factor impact sale insur reauthor exist
patient reduc averag number script fill quarter
could amount fewer script per manag net revenu per
month revenu could sequenti lower end phenomenon
compound medicar part donut hole impact revenu
much dynam understood like reflect number somewhat
concern impact subsequ quarter still difficult
forecast impact given uncertainti around virtual sale rep interact
current forecast sequenti growth could mute new patient
start slow given uncertainti maintain neutral rate cut
tp
impact potenti greater compani coverag
think combin clinic trial delay potenti commerci headwind could
make less attract investor think develop
treatment prophylaxi impact long-term busi outlook coverag
near-term seen headlin provid upsid benefit unfortun neurocrin
activ involv impact
adjust valuat metric adjust valuat share use
wacc also cut tvgr tp base sum
part dcf analysi risk commerci market price regulatori
focu point call expect much discuss center ingrezza
dynam go forward beyond commerci could get detail
delay launch opicapon pdufa current state clinic trial
across compani
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc commercial-stag biopharmaceut
compani discov develop intend commerci drug
treatment neurolog endocrin relat diseas
blue sky valuat base fda approv elagolix uterin
fibroid opicapon parkinson diseas also assum posit
pivot congenit adren hyperplasia posit data
gene therapi asset vy-aadc furthermor
assum better expect growth ingrezza orilissa
endometriosi furthermor assum better expect growth
ingrezza orilissa endometriosi
grey sky valuat assum fda approv elagolix uterin
fibroid opicapon parkinson diseas assum neg top-line
pivot congenit adren hyperplasia grey sky also
assum lower expect revenu ingrezza orilissa
 close
figur goals- provid ahead
model chang head result weve adjust expens assumpt
increas sg reduc slightli year lower cost
due delay trial delay opicapon launch note forecast
non- number consensu still report expens earn thu continu
report metric includ share base compens estim
mileston income/ expens forecast mileston incom
like approv elagolix uterin fibroid mileston
payment bial like april approv opicapon chang result
gaap ep vs consensu fy vs
consensu figur detail
figur nbix- estim cs vs consensu
valuat price target per share base sum-of-the-part
dcf analysi assum discount rate assign
termin growth free cash flow assum neurocrin small molecul asset
retain signific valu beyond patent expir commerci exclus yet
believ compani on-going invest could success replac
revenu long-term
base sotp dcf primarili driven valuat sale ingrezza td
valu opicapon risk adjust royalti orilissa endometriosi
valu po royalti uterin fibroid indic risk
adjust valu program valu risk
adjust combin unalloc corpor expens net cash
sotp dcf valu neurocrin figur detail
neurocrin revenu incom loss expens incom cs dilut cs charl martineau pm univers toronto april
blue sky valuat base fda approv elagolix uterin
fibroid opicapon parkinson diseas also assum posit pivot
congenit adren hyperplasia posit data gene therapi asset vy-aadc
voyag transact furthermor assum better expect growth
ingrezza orilissa endometriosi
grey grey sky valuat assum fda approv elagolix uterin
fibroid opicapon parkinson diseas assum neg top-line pivot
congenit adren hyperplasia grey sky also assum lower expect revenu
ingrezza orilissa endometriosi
clinic development valuat share upsid potenti base
outcom clinic trial neurocrin late-stag asset shown
clinic ineffect unsaf would expect neg pressur share
regulatori food drug administr fda european medicin agenc ema
regulatori bodi approv requir neurocrin market sell
therapeut delay outright reject approv investig asset could
neg impact futur cash flow valu neurocrin share
furthermor fda ema could revok market author market
product due safeti efficaci concern
commerci eu sale us sale royalti drive major cash flow
earn estim sale wors consensu expect could see
neg impact share
external/market risk biotechnolog remain volatil sector affect
overal economi neg polici develop and/or weaken
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
